Brief: Jazz Pharmaceuticals Enters Definitive Agreement With Redx Pharma To Acquire Global Rights To KRAS Inhibitor Program

Redx Pharma

07/02/2024 07:27

Feb 7 (Reuters) - Jazz Pharmaceuticals PLC  JAZZ.O :
    * JAZZ PHARMACEUTICALS ENTERS DEFINITIVE AGREEMENT WITH REDX
PHARMA TO ACQUIRE GLOBAL RIGHTS TO KRAS INHIBITOR PROGRAM
    * JAZZ PHARMACEUTICALS PLC - UNDER AGREEMENT JAZZ WILL MAKE
AN
UPFRONT PAYMENT TO REDX OF $10 MILLION
    * JAZZ PHARMACEUTICALS PLC - PRECLINICAL PROGRAM EXPANDS
JAZZ'S
PIPELINE OF TARGETED ONCOLOGY THERAPIES
    * JAZZ PHARMACEUTICALS PLC - REDX IS ELIGIBLE TO RECEIVE UP
TO
$870 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE
PAYMENTS FROM JAZZ

Source text for Eikon:  ID:nPrenpy32a 
Further company coverage:  JAZZ.O 

 ((Reuters.Briefs@thomsonreuters.com;))